

## **Abzyme Therapeutics Secures Key Patent for Novel pH-Dependent Anti-CD3 Antibody**

**Royersford, PA, October 29, 2024** – Abzyme Therapeutics LLC, a biotechnology company focused on developing innovative antibody-based therapies, announced today that it has been awarded U.S. Patent No. 12,116,411 for its groundbreaking anti-CD3 antibody technology. This patent solidifies Abzyme's intellectual property position in the field of therapeutic antibody development and underscores its commitment to advancing novel cancer treatments.

The newly patented antibodies exhibit a novel pH-dependent binding profile, demonstrating high affinity to human CD3 at acidic pH conditions found in solid tumors. This specificity minimizes off-target binding to normal tissues, a major challenge in antibody-based therapies. By leveraging the acidic tumor microenvironment, Abzyme's antibodies improves tumor targeting and while reducing toxicity.

"We are thrilled to secure this important patent, which validates our innovative approach to antibody design", said Dr. Tran, CEO and co-founder of Abzyme Therapeutics. "These antibodies represent a significant step forward in developing more effective and targeted therapies for cancer patients. pH-dependent anti-CD3 antibodies are just the beginning of our conditionally-active antibody engineering platform. The anti-CD3 antibody is just one example of the conditionally-active antibodies we are creating to target solid tumors".

Abzyme's conditionally-active antibody platform has the potential to be used in various therapeutic applications, including:

- **Antibody-drug conjugates (ADCs):** Delivering potent cytotoxic payloads directly to tumor cells.
- **T-cell engaging immunotherapies (TEIs):** Harnessing a patient's immune cells to attack cancer.
- **Chimeric antigen receptor (CAR) T-cell therapy:** Engineering patient's T cells to recognize and destroy tumor cells.

This breakthrough has the potential to transform cancer treatment, addressing a critical unmet need for more targeted and effective therapies.

### **About Abzyme Therapeutics**

Abzyme Therapeutics is a biotechnology company dedicated to discovering and developing novel antibody-based therapies for a range of diseases. The company's focus is on creating innovative solutions to address unmet medical needs and improve patient outcomes.

For further information and interest in licensing these novel anti-CD3 antibodies, please contact:

#### **Abzyme Therapeutics LLC**

Stephen Manobianco, MBA.

Director of Business Development

Phone: 610-205-9650

E-mail: [manobianco@abzymetx.com](mailto:manobianco@abzymetx.com)